

A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients.

Baohui Zhang

Department of Physiology, School of Life Science, China Medical University, Shenyang 110122, China

Bufu Tang

Department of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.

Jianyao Gao

Department of Radiation Oncology, the First Affiliated Hospital of China Medical University, Shenyang, China.

Jiatong Li

Department of Orthopedics, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.

Lingming Kong

Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China

Ling Qin (✉ qinlingling@yahoo.com)

Department of Physiology, China Medical University, Shenyang, People's Republic of China

<https://orcid.org/0000-0001-8717-3833>

Research

Keywords: hypoxia, hepatocellular carcinoma, prognostic, diagnostic, immune microenvironment

Posted Date: August 12th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-17783/v3>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on September 4th, 2020. See the published version at <https://doi.org/10.1186/s12967-020-02492-9>.

Abstract

Background

Hypoxia plays an indispensable role in the development of hepatocellular carcinoma (HCC). However, there are few studies on the application of hypoxia molecules in the prognosis predicting of HCC. We aim to identify the hypoxia-related genes in HCC and construct reliable models for diagnosis, prognosis and recurrence of HCC patients as well as exploring the potential mechanism.

Methods

Differentially expressed genes (DEGs) analysis was performed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database and four clusters were determined by a consistent clustering analysis. Three DEGs closely related to overall survival (OS) were identified using Cox regression and LASSO analysis. Then the hypoxia-related signature was developed and validated in TCGA and International Cancer Genome Consortium (ICGC) database. The Gene Set Enrichment Analysis (GSEA) was performed to explore signaling pathways regulated by the signature. CIBERSORT was used for estimating the fractions of immune cell types.

Results

A total of 397 hypoxia-related DEGs in HCC were detected and three genes (PDSS1, CDCA8 and SLC7A11) among them were selected to construct a prognosis, recurrence and diagnosis model. Then patients were divided into high- and low-risk groups. Our hypoxia-related signature was significantly associated with worse prognosis and higher recurrence rate. The diagnostic model also accurately distinguished HCC from normal samples and nodules. Furthermore, the hypoxia-related signature could positively regulate immune response. Meanwhile, the high-risk group had higher fractions of macrophages, B memory cells and follicle-helper T cells, and exhibited higher expression of immun checkpoints such as PD1 and PDL1.

Conclusions

Altogether, our study showed that hypoxia-related signature is a potential biomarker for diagnosis, prognosis and recurrence of HCC, and it provided an immunological perspective for developing personalized therapies.

Background

Hepatocellular carcinoma (HCC) accounts for 85% of liver cancers, and the disease burden of HCC is increasing globally[1]. Although progress on treatment strategies for HCC has been made, the overall 5-year survival rate for HCC patients remains less than 20%[2]. Nowadays, the research of molecular mechanism based on bioinformatics analysis has become one of the most important tools for cancer research[3, 4]. Therefore, it is of great significance to search for molecular markers for early diagnosis,

survival prediction and recurrence monitoring of HCC, which can improve patients' stratification and optimize medical intervention. The low rate of early diagnosis and high rate of metastasis and recurrence have considerable impact on the prognosis of HCC patients, which are mainly related to the invasiveness and high proliferative activity of tumor cells[5]. However, the mechanism of tumor progression has not been completely realized.

Hypoxia is an intrinsic characteristic of solid tumors due to the imbalance between the rate of tumor cell proliferation and nutrient supply of vascular[6]. Existing studies have recognized the critical roles played by hypoxia on tumor angiogenesis, cell proliferation, as well as cell differentiation and apoptosis[7, 8]; Liver is one of the three organs most susceptible to hypoxia and it has been found that hypoxia was involved in the metastasis, poor prognosis and radiation resistance of HCC [9, 10]. Nevertheless, its potential regulatory mechanism remains unclear. In recent years, there is an increasing interest in the tumor microenvironment which immune cells in it play a crucial role in the progression of tumor[11-13]. Previous studies have shown that hypoxia can regulate the status of tumor immune microenvironment, such as promoting the recruitment of innate immune cells and interfering with the differentiation and function of adaptive immune cells[14]. Therefore, further study on the relationship between hypoxia and immunity in HCC is required in order to develop new therapeutic strategies.

Immunocheckpoint inhibition has become an effective and frequently-used way of immunotherapy[15]. As a new feature of cancer, tumor mutation burden (TMB) is defined as the total number of somatic mutations in the genome of tumor cells[16], and high TMB may produce many neoantigens to stimulate the anti-tumor immune response[16]. Clinical data demonstrated that patients with high TMB were more likely to benefit from immunocheckpoint inhibitor therapy[17, 18], which suggesting that TMB should be an appropriate biomarker for assessing the effect of immune treatment.

In this study, we analyzed hypoxia-related genes in HCC by using TCGA and GEO database and constructed a consistent clustering. Then we built the prediction model for diagnosis, recurrence and prognosis of HCC. We also explored the association of hypoxia with immune infiltration and immunocheckpoints in HCC. These findings may make a meaningful contribution to the development of comprehensive therapeutic strategies for HCC patients.

Methods

Identification of differentially expressed genes (DEGs) between HCC and noncancer tissues

The differentially expressed genes (DEGs) related to hypoxia and HCC were identified with limma, an R package[19]. The DEGs with an absolute log₂-fold change (FC) > 1 and an adjusted P value < 0.05 were considered for further analysis.

Acquisition of hypoxia-related genes associated with HCC

The mRNA expression profiles and corresponding clinical information associated with HCC patients were obtained from The Cancer Genome Atlas—Liver Hepatocellular Carcinoma dataset (TCGA-LIHC) (including 370 HCC and 50 normal tissue samples). The mRNA-sequencing data of Human HCC cell lines were obtained from the Gene Expression Omnibus database (GEO), which included GSE59729 (with gene expression profiles of Huh-7 cells under normoxia and hypoxia for 24 hours) and GSE41666 (with gene expression profiles of HepG2 cells exposed to normoxia and hypoxia for 24 hours). A total of 1,401 hypoxia-related DEGs expressed by HepG2 from GSE41666 and 1,279 hypoxia-related DEGs expressed by Huh7 from GSE59729 were matched with HCC-related information obtained from TCGA. The data from TCGA and GEO databases are freely available to the public, and this research also strictly followed access policies and publication guidelines, therefore this study did not require ethical review and approval from an Ethics Committee.

Classification of molecular subgroups by consistent clustering

The ConsensusClusterPlus package in R software was utilized for the consistent clustering to determine subgroups of HCC samples from TCGA. The Euclidean squared distance metric and the K-means clustering algorithm was used for classifying samples into k clusters with k=2 to k=9. About 80% of the samples were selected in each iteration, and the results were compiled over 100 iterations. The results are presented in the form of heatmaps of the consistency matrix generated by pheatmap R package, and the optimal number of clusters was determined by the consistent cumulative distribution function (CDF) graph and the delta region graph[20]. We considered that the optimal number of clusters should satisfy the following criteria: high consistency of clustering, low coefficient of variation, and no significant increase in the area under the CDF curve. According to the relative non-significant change of the area under the CDF curve, the corresponding number of categories was determined.

Establishment and validation of a prognostic predictive signature

The univariate Cox regression analysis was conducted to identify the prognostic value of the DEGs for OS and genes with a P value <0.05 were considered statistically significant. Subsequently the Least absolute shrinkage and selection operator (LASSO) Cox regression[21] was performed by using the glmnet R package to shrink scope of gene screening, we performed 1,000 substitution samples of the dataset and selected the markers with repeat occurrence frequencies of more than 900. Finally, a multivariate Cox regression analysis was performed to identify highly correlated genes and construct the prognostic gene signature. The regression coefficient (β) was derived from multivariate Cox regression analysis and the Prognosis Index (PI) = (β_{mRNA_1} * expression level of mRNA₁) + (β_{mRNA_2} * expression level of mRNA₂) + ... + (β_{mRNA_n} * expression level of mRNA_n). Based on the optimal cut-off value determined by using X-tile software, patients with survival data were divided into high- and low-risk groups. The Kaplan-Meier survival analysis was used to evaluate the predictive ability of the prognostic model, which was further validated in the ICGC dataset.

Independence of the prognostic gene signature from other clinical characteristics

Univariate and multivariate Cox proportional hazard regression analyses were performed to determine whether the predictive ability of prognostic model was independent of conventional clinical characteristics. A bilateral P value <0.05 was considered statistically significant. The hazard ratio (HR) and 95% confidence intervals were calculated.

Construction and evaluation of a predictive nomogram

All independent prognostic factors were used to build a nomogram[22] in order to evaluate the 1-, 3-, and 5-year survival probability for patients with HCC. The calibration plot was performed for an internal validation to verify the accuracy. Time-dependent receiver operating characteristic (ROC) analysis was conducted to evaluate the predictive performance of the nomogram. Decision curve analysis (DCA) was performed to assess the clinical net benefit[23].

Gene set enrichment analysis

Gene set enrichment analysis (GSEA)[24] was performed using prognosis index with ClusterProfiler package to identify signaling pathways regulated by the hypoxia-related signature. The correlation coefficients, CI and P-values were calculated using R software. P<0.05 was considered statistically significant.

Estimation of immune cell type fractions

CIBERSORT is a method for characterizing the cell composition from their gene expression profiles and is the most frequently cited tool for estimating and analyzing immune cells infiltration[25]. We utilized CIBERSORT to estimate the fractions of immune cell types between low- and high-risk groups. The sum of all the estimated immune cell type scores is equal to 1 in each sample.

Real-time PCR analysis

Total RNA was isolated using Trizol reagent (Invitrogen, Eugene, OR, USA). The first-strand cDNA was synthesized with Prime-Script RT Master Mix (TaKaRa) followed by qPCR detection using the SYBR Green Master Mix (TaKaRa). The following primers were used: PDSS1 F: 5'- AGCCAACAGTTGTAAAGCAGTATTT -3' and R: 5'- GTTTGTGTCACACCATCACTCTGT -3'; CDCA8 F: 5'- GCACAGCGAGGTTTTGCTCA -3' and R: 5'- AACTGGGTAGGGACGAGGA -3'; and SLC7A11 F: 5'- ATGGGACAAGAAACCCAGGTG -3' and R: 5'- TCCCTATTTTGTGTCTCCCCTTG -3'.

Statistical analysis

Continuous variables were summarized as the mean±standard deviation (SD). Differences between groups were compared by Wilcoxon test through R software. Different hypoxia subtypes were compared by using the Kruskal–Wallis test. The significance of survival time differences was calculated using the log-rank test with a threshold of P-value < 0.05. Kaplan Meier curves were plotted to show the survival time differences.

Results

Identification of DEGs related to hypoxia in HCC

We identified DEGs ($|\text{LogFC}| > 1$, $P < 0.05$) using the mRNA expression profile between HCC and adjacent noncancerous tissues from TCGA database (Table 4). Then we matched the differentially expressed mRNA-sequencing data between hypoxia-treated and untreated HCC cell lines in GEO database (Table 2-3) and obtained 397 DEGs which were related to hypoxia in HCC (Figure 1A). By using the Gene Ontology (GO) enrichment and functional analysis, we found that these genes are enriched in DNA replication, cell division, cell cycle and also somatic diversification of immune receptors (Figure 1B).

Using the hypoxia-related genes for the consistent clustering of HCC molecular subgroups

Consistent clustering of 397 hypoxia-related DEGs were constructed by using the ConsensusClusterPlus R software package. The average clustering consistency and inter-cluster variation coefficient of each cluster number were calculated and the optimal cluster number was determined by using CDF. As shown in Figure 2A, the clustering outcome was stable when $k=4$. We further analyzed CDF delta area curve and found that the area under the CDF curve tended to be stable after 4 clusters (Figure 2B). The item-Consensus Plot also showed that the sample classification was relatively stable when the clustering number was selected as 4 (Figure 2C). Finally, we built a consensus matrix graph which 397 DEGs were assigned to 4 clusters in order to evaluate the composition and quantity of clustering more intuitively (Figure 2D). The heatmap of 397 hypoxia-related DEGs in 4 clusters was shown in Figure 2E.

The results from Kaplan–Meier plot showed the significant differences in survival probability and recurrence rate among these 4 subgroups. Compared to the other three clusters, the samples in cluster-2 had the worst prognosis and the highest recurrence rate (Figure 3A-B). We further analyzed the distribution of AFP, gender, degree of vascular infiltration, TNM stage, pathological grade, and age in these 4 subgroups (Figure 3C). Samples in cluster-4 were associated with high AFP expression level, undifferentiated tumor cells and lymphatic metastasis while cluster-3 showed high incidence of distant metastasis; cluster-2 had a higher degree of vascular invasion and more tumor cells with low differentiation. Moreover, most of patients in cluster-2 were male and generally aged between 65 and 70 years. It is worth noting that patients in cluster-2 showed the highest TMB than other three clusters (Figure 3D-E), suggesting a benefit of immunotherapy.

Construction and validation of a hypoxia-related prognosis signature with good performance

We performed a univariate Cox regression and found 291 DEGs significantly related to OS of HCC patients ($P < 0.01$) (Table 1). Then a Lasso-penalized Cox analysis was performed to further shrink the scope of gene screening. The penalty parameter was established through 10-fold cross-validation. We selected 11 DEGs, which appeared over 900 times of a total of 1000 repetitions (Figure S1). Finally, by analyzing a multivariate Cox regression, three genes (PDSS1, SLC7A11, CDCA8) conforming to the proportional hazards (PH) assumption were selected to build a prognostic model as follows: the

prognostic index (PI) = (0.337 * expression level of PDSS1) + (0.383* expression level of SLC7A11) + (0.356* expression level of CDCA8). The optimal cut-off value of 2.296 for the risk score was produced using X-tile software and patients with survival time from TCGA-LIHC were divided into a high- and low-risk group. The K-M curve showed that the OS of the high-risk group was significantly poorer than that of low-risk group ($P < 0.001$, HR=4.76) (Figure 4A). The area under the time-dependent ROC curves (AUCs) for 0.5-, 1-, 3- and 5-year overall survival (OS) were 0.76, 0.78, 0.7 and 0.7, respectively, indicating a good predictive performance of this prognostic model (Figure 4C).

We further validated the prediction ability of this prognostic signature using HCC samples from ICGC database (Table 5). Consistent with above results, HCC patients were divided into a high- and low-risk group with an optimal cut-off value of 18.812 and patients in the high-risk group had poorer survival probability than the low-risk group ($P < 0.001$, HR=5.26) (Figure 4B). The AUCs of the three-gene prognostic model were 0.68, 0.75, 0.77 and 0.77 for the 0.5-, 1-, 3- and 4-year survival times (Figure 4D). Meanwhile, we attempted to compare the hypoxia-related signature with other prognostic models published previously[26, 27]. For the hypoxia-related signature, methylation-driven prognostic model and three-gene prognostic model, the AUCs was 0.78, 0.67 and 0.67 in TCGA cohort and 0.75, 0.64 and 0.64 in ICGC cohort, respectively (Figure S2). Taken together, our prognostic model showed a higher specificity and sensitivity.

Evaluating the independent role of prognostic signature and building a predictive nomogram for OS prediction in the HCC cohort from TCGA

Univariate and multivariate Cox regression analysis were used to evaluate whether the predictive value of the prognostic model was independent of other traditional clinical characteristics. The results showed that the TNM stage ($P < 0.05$, HR=1.828) and the risk score ($P < 0.05$, HR=1.683) were independent prognostic factors for OS (Figure 5A). Then we built a predictive nomogram which may be helpful to accurately predict a certain clinical outcome (Figure 5B)[28]. Each level of independent factors was assigned one score and a total score was calculated by summing up the scores in each individual. The survival probability for the individuals at 1-, 3-, and 5- year was obtained through the function conversion relationship of total scores. The calibration plot for internal validation of the nomogram showed better consistency between the predicted OS outcomes and actual observations (Figure 5C-E). The C-index was 0.54, 0.65 and 0.66 for the TNM stage, the prognostic model and the nomogram (95%CI: 0.58–0.73), further indicating that our nomogram had a higher predicting consistency. The AUCs of the nomogram at 1-, 3- and 5- year OS were 0.672, 0.684 and 0.675, which were better than the models with single independent factors (Figure 5F-H). The DCA was used to evaluate guiding significance of these models for clinical application and the results showed that the combined model was the best for predicting the OS (Figure 5I-K). For the hypoxia-related signature, methylation-driven prognostic model and three-gene prognostic model, the C-index reached 0.70, 0.64 and 0.64 in TCGA database and 0.74, 0.65 and 0.65 in ICGC database, indicating a more sensitive and valuable predictive performance of hypoxia-related model.

Evaluation of the hypoxia-related genes for predicting the recurrence of HCC patients

TCGA-LIHC cohort with relapse-free survival (RFS) information and recurrent status of HCC patients was utilized as a training set for an independent evaluation, and the HCC cohort from GSE14520 (Table 6) was used as a validation set. Based on these three hypoxia-related genes, we constructed a recurrence signature by using the regression coefficient (β') of multivariate Cox proportional hazards. The prognostic index (PI) = (0.060 * expression level of PDSS1) + (0.045* expression level of SLC7A11) + (0.041* expression level of CDCA8). In both training and validation set, patients were divided into a high- and low-risk group based on the risk score of 0.953 and 1.247. The distribution of risk score and gene expression was examined (Figure 6A, S3A). From the results of Kaplan–Meier survival analysis, patients in high-risk group had significantly higher recurrence rate than the low-risk group. (Figure 6B, 6E) and we also performed ROC analysis to evaluate the predictive accuracy of our recurrence model (Figure 6C, S3B). Compared with other prognostic models, the AUCs was 0.64, 0.6 and 0.6 for the hypoxia-related signature, methylation-driven prognostic model and three-gene prognostic model (Figure 6D). All these results indicated a more reliable predictive ability of our hypoxia-related recurrence model.

Building a nomogram for predicting recurrent probability of HCC patients and evaluating its predictive performance

We performed a univariate and multivariate Cox regression analysis and screened out three independent factors related to the recurrence of HCC ($P < 0.05$) (including the age, the TNM stage and the risk score of our recurrence signature) (Figure 7A). The nomogram for recurrence prediction was built by integrating these three factors (Figure 7B) The level of each factor was assigned according to the regression coefficient of each influencing factor, and then the scores were added to obtain the total score. Finally, the predicted value of the individual outcome was calculated through the function conversion relationship between the total score and the probability of occurrence of outcome. The calibration plot of the nomogram showed a consistency between the prediction and observation (Figure 7C-E). The C-index was 0.62, 0.56, 0.63 and 0.71 for the age, TNM stage, the prognostic model and the nomogram (95%CI: 0.64-0.78). From the results of ROC analysis in Figure 7F-H, the AUCs of nomogram at 1-, 3-, 5-year was 0.746, 0.741, 0.717, respectively, which was obviously higher than other models with single independent factors. The DCA curves showed that the combined model obtained a higher net benefit (Figure 7I-K). Through comparative analysis with other recurrence models, the C-index was 0.60, 0.59 and 0.59 for the hypoxia-related signature, methylation-driven prognostic model and three-gene prognostic model. These results indicated that our recurrent nomogram performed a better sensitivity and specificity of HCC recurrence prediction and could provide clinicians with more specific guidelines.

Establishment of a diagnostic model based on hypoxia-related genes in HCC

As the diagnosis is of great importance for proper management of patients, we further analyzed whether hypoxia-related genes also contribute to more accurate diagnosis of HCC. A diagnostic model based on these three hypoxia-related genes was constructed by using a stepwise logistic regression method. The diagnostic score was finally identified as follows: $\text{logit}(P = \text{HCC}) = 1.171 + (-0.571) \times \text{PDSS1 expression}$

level + (-1.019) × SLC7A11 expression level + (-2.037) × CDCA8 expression level. In TCGA cohort with 50 normal samples paired 50 HCC samples, our diagnostic model achieved a sensitivity of 94% and a specificity of 92% (Figure 8A). We also utilized ICGC cohort with 190 normal samples paired 219 HCC samples as a validation set, and the diagnostic model obtained a sensitivity of 90% and a specificity of 94% (Figure 8C). As shown in ROC analysis (Figure 8B, D), the AUCs of our model reached 0.986 and 0.962 in TCGA and ICGC cohort, indicating a satisfactory accuracy of prediction. To further verify the clinical application of the model, we collected a group of patient-derived tissues, in which 13 tumor tissues were paired with 13 adjacent tissues. The results were proved to be satisfactory as a sensitivity of 92% and a specificity of 92% were calculated. (Figure 8E-F)

Liver nodule is a kind of hepatic hyperplasia caused by various factors. It is indistinguishable from the early stage of liver cancer, and the corresponding treatment methods are different. We aimed to establish a diagnostic model by using a stepwise logistic regression method to better distinguish liver cancer from hepatic nodules. The diagnostic score was identified as follows: $\text{logit}(P = \text{HCC}) = -45.308 + 0.628 \times \text{PDSS1 expression level} + 8.452 \times \text{SLC7A11 expression level} + 4.047 \times \text{CDCA8 expression level}$. We tested the diagnostic performance of the model in two databases, GSE6764 and GSE89377 cohort. One achieved a sensitivity of 88.57% and a specificity of 82.35%, the other one achieved a sensitivity of 87.5% and a specificity of 77.27% (Figure 9A, C). The AUCs for GSE6764 and GSE89377 were 0.934 and 0.935 (Figure 9B, D). These data further confirmed that the diagnostic model was a novel predictive tool with high accuracy and potential clinical value.

Validation of the expression and genetic alterations and independent prognostic analysis for genes

We detected genetic alterations of the three genes from cBioportal database[29] and found that PDSS1, SLC7A11 and CDCA8 possessed genetic alterations of 9%, 3% and 5% (Figure 10A). These results helped explain that the abnormal gene expression may be attributable to genetic alterations. To further confirm the expression level of each gene in HCC, we used TCGA database containing 50 tumor and 50 normal samples. We found all the three genes were highly expressed in HCC compared with in normal liver tissues (Figure10B-D). The assessment of mRNA expression for each gene in HCC clinical specimens shows that it is higher in tumor tissues ($P < 0.05$) (Figure 10E-G). The protein expression of CDCA8 and SLC7A11 (also known as xCT) by IHC were showed in Figure S4. We also detected the mRNA expression of these three genes in normal hepatocytes and different hepatoma cell lines. The results showed that PDSS1, SLC7A11 and CDCA8 were significantly upregulated in hepatoma cell lines ($P < 0.05$) (Figure 10H-J). Moreover, by analyzing gene expression in GSE6764 cohort, we found that the expression levels of PDSS1, CDCA8 and SLC7A11 were significantly higher in tumor tissue than those in liver nodules (Figure10K-M). We also attempted to explore the interaction between each two genes. As shown in Figure10O-Q, there was a sort of synergy between CDCA8 and PDSS1 as well as SLC7A11 ($P < 0.05$).

Kaplan-Meier Plotter database[30] was used in order to analyze the effect of single gene on HCC prognosis. The results showed that the high-expression level of PDSS1, CDCA8 or SLC7A11 was separately related to a shorter overall survival time (Figure11A-C). In addition, the progression-free

survival (PFS) analysis, which can better reflect tumor progression and predict clinical benefits, also showed an association between higher expression level of a single gene and faster disease progression (Figure11D-F). To achieve a better understanding of the functional characteristics of three genes, we performed Gene set enrichment analysis, which showed that some immune-related pathways, such as JAK–STAT3 signaling, The NF-kappa B signaling, were highly active in the high-risk group (Figure11G-I).

Comparison of the immune microenvironment between high- and low-risk groups

Tumor immune cell infiltration refers that the immune cells move from the blood to the tumor tissue. The immune cells in tumors are closely related to clinical outcomes and they are most likely to serve as drug targets to improve survival rate [31]. Since these three genes have been found to enriched in some immune pathways, we then analyzed the relationship between hypoxia-related genes and immune cell infiltration as well as immune checkpoints in HCC. Patients in the high-risk group had higher ratios of M0 macrophages, memory B cells and follicular helper T cells than those in the low-risk group ($P < 0.05$) (Figure12A-C). Moreover, we found that the expression levels of TIM3, B7H3, CTLA4, PD1 and PDL1 in the high-risk group were obviously higher than those in the low-risk group ($P < 0.05$) (Figure12D-H). Our findings lead us to conclude that tumor immune microenvironment may be responsible for the prognosis of HCC patients with high expression of hypoxia-related genes.

Discussion

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death in the world, and the development of HCC is a complicated process influenced by various factors[32]. Though some progresses have been made in the treatments of HCC, such as surgical resection, microwave ablation and liver transplantation, the prognosis of HCC patients remains poor[33]. In recent years, high-throughput sequencing and data analysis have gradually become more significant tools for biomedical research, which can identify biomarkers for prognosis predicting, recurrence monitoring as well as clinical stratification[3, 34, 35]. Therefore, it is urgent to apply to HCC and explore key targets for the treatment.

Hypoxia is a prominent characteristic of malignant tumors, especially in HCC[36]. It was demonstrated in several studies that hypoxia was involved in the aggressive development of HCC[8]. Nevertheless, due to the multiple roles of hypoxia, the specific role of hypoxia in the development of liver cancer remains unclear [37]. In this study, we identified three hypoxia-related genes (PDSS1, CDCA8 and SLC7A11) closely relating to HCC. CDCA8, involving in protein metabolism and mitosis, has been demonstrated to participate in malignant progression of tumor cells and lead to poor prognosis in liver, stomach and lung cancer[38]. SLC7A11 (also known as xCT) plays a critical role in maintaining redox homeostasis and has been confirmed to be associated with the prognosis of HCC[39]. PDSS1 is involved in coenzyme Q biosynthesis, but little is known about the relationship between PDSS1 and cancer[40]. Our results showed that this three-gene signature was an independent factor affecting the prognosis of HCC and the model had a better predictive performance on both prognosis and recurrence. What's more, the diagnostic model based on these three genes had a high sensitivity and specificity, and could help distinguish HCC from

dysplastic nodules. Consensus Clustering is a common method for classification of cancer subtypes. We divided the samples into 4 clusters according to the hypoxia-related DEGs dataset of HCC and compared the differences among clusters. It should be pointed out that cluster-2 had a higher TMB, indicating that patients in cluster-2 were more likely to benefit from immunotherapy[41].

Much work so far has focused on the role of hypoxia in regulating the immune response in tumors. Hypoxia can interfere with the differentiation and function of immune cells through regulating the expression of co-stimulating receptors and the types of cytokines[42, 43]. The immune system is able to recognize and eliminate tumor cells through innate and adaptive mechanisms. However, the tumor microenvironment could suppress this anti-tumor response through a number of inhibitory pathways which were known as immunotherapy[44]. Our results of GSEA indicated that hypoxia-related signature could positively regulate some immune signaling pathways. The high-risk group based on the expression level of hypoxia-related genes had a higher infiltration proportion of macrophages, B memory cells and follicle-assisted T cell, as well as higher expression levels of immune checkpoints. These evidence for the association between hypoxia and immunity highlighted the importance of immunotherapy for HCC patients with high expression level of three hypoxia-related genes.

However, some limitations of this study should be noted. First, the process of adjusting the weight of regression coefficient in LASSO might ignore some important factors contributing to HCC prognosis. Second, our nomogram did not perform external validation as there was a lack of specific clinical data in ICGC database. Moreover, our retrospective findings need to be further validated in prospective research. Finally, the complex interaction between tumor cells and immune cells in hypoxic environments remains to be further explored.

Conclusion

In summary, we identified the hypoxia-related DEGs between HCC and normal tissues and clustered HCC samples into 4 subgroups. We established the diagnosis, prognosis and recurrence models based on three hypoxia-related genes, which performed favorable diagnosis and prediction performance for HCC. Finally, we identified higher proportions of immune cell infiltration and immunotherapy expression in the high-risk group, which may be more sensitive to benefit from immunotherapy.

Abbreviations

HCC Hepatocellular carcinoma

TCGA The Cancer Genome Atlas

GEO Gene Expression Omnibus

ICGC International Cancer Genome Consortium

DEGs Differentially expressed genes

OS Overall survival

ROC Receiver operating characteristic

AUC Area under the ROC curve

DCA Decision curve analysis

PD1 Programmed cell death-1

PDL1 Programmed cell death 1 ligand 1

GSEA Gene Set Enrichment Analysis

TMB Tumor mutation burden

CDF Cumulative distribution function

LASSO Least absolute shrinkage and selection operator

PI Prognosis Index

HR Hazard ratio

GO Gene Ontology

RFS Release-free survival

PFS Progression-free survival

Declarations

Acknowledgments

Not applicable.

Authors' contributions

Conception and design: BZ and BT. Acquisition of data: BZ and BT. Analysis and interpretation of data: BZ and BT. Drafting the article: BZ, BT and LQ. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Study supervision: LQ.

Funding

None.

Availability of data and materials

The data used to support the findings of this study are available from the corresponding author upon request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests

Contributor Information

Ling Qin, Email: qinlingling@yahoo.com.

Baohui Zhang, Email: 18102489912@163.com

Bufu Tang, Email: tangbufu@hotmail.com

Jianyao Gao. Email: gaojygao@163.com

Jiatong Li, Email: jtli1995@163.com

Lingming Kong, Email: konglingmingklm@163.com

References

1. El-Serag HB: **Hepatocellular carcinoma**. *N Engl J Med* 2011, **365**:1118-1127.
2. Nault JC, Villanueva A: **Biomarkers for hepatobiliary cancers**. *Hepatology* 2020.
3. Kyrochristos ID, Ziogas DE, Roukos DH: **Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy**. *Medicinal research reviews* 2019, **39**:1205-1227.
4. Yin F, Shu L, Liu X, Li T, Peng T, Nan Y, Li S, Zeng X, Qiu X: **Microarray-based identification of genes associated with cancer progression and prognosis in hepatocellular carcinoma**. *J Exp Clin Cancer Res* 2016, **35**:127.
5. Schafer DF, Sorrell MF: **Hepatocellular carcinoma**. *Lancet* 1999, **353**:1253-1257.
6. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC: **The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy**. *Br J Radiol* 1953, **26**:638-648.

7. Nishida N, Kudo M: **Oxidative stress and epigenetic instability in human hepatocarcinogenesis.** *Digestive diseases (Basel, Switzerland)* 2013, **31**:447-453.
8. Wu X-Z, Xie G-R, Chen D: **Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.** *Journal of gastroenterology and hepatology* 2007, **22**:1178-1182.
9. Erler JT, Giaccia AJ: **Lysyl oxidase mediates hypoxic control of metastasis.** *Cancer research* 2006, **66**:10238-10241.
10. Graham K, Unger E: **Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment.** *International journal of nanomedicine* 2018, **13**:6049-6058.
11. Tlsty TD, Coussens LM: **Tumor stroma and regulation of cancer development.** *Annual review of pathology* 2006, **1**:119-150.
12. Mantovani A, Allavena P, Sica A, Balkwill F: **Cancer-related inflammation.** *Nature* 2008, **454**:436-444.
13. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G: **Inflammation and cancer: how hot is the link?** *Biochemical pharmacology* 2006, **72**:1605-1621.
14. Palazon A, Goldrath AW, Nizet V, Johnson RS: **HIF transcription factors, inflammation, and immunity.** *Immunity* 2014, **41**:518-528.
15. Chen Y-P, Zhang Y, Lv J-W, Li Y-Q, Wang Y-Q, He Q-M, Yang X-J, Sun Y, Mao Y-P, Yun J-P, et al: **Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.** *Theranostics* 2017, **7**:3585-3594.
16. Schumacher TN, Schreiber RD: **Neoantigens in cancer immunotherapy.** *Science (New York, NY)* 2015, **348**:69-74.
17. Wang X, Li M: **Correlate tumor mutation burden with immune signatures in human cancers.** *BMC immunology* 2019, **20**:4.
18. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, et al: **Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.** *Genome medicine* 2017, **9**:34.
19. Diboun I, Wernisch L, Orengo CA, Koltzenburg M: **Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma.** *BMC Genomics* 2006, **7**:252.
20. Wilkerson MD, Hayes DN: **ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking.** *Bioinformatics* 2010, **26**:1572-1573.
21. Tibshirani R: **The lasso method for variable selection in the Cox model.** *Stat Med* 1997, **16**:385-395.
22. Iasonos A, Schrag D, Raj GV, Panageas KS: **How to build and interpret a nomogram for cancer prognosis.** *J Clin Oncol* 2008, **26**:1364-1370.
23. Vickers AJ, Cronin AM, Elkin EB, Gonen M: **Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers.** *BMC Med Inform Decis Mak* 2008, **8**:53.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: **Gene set enrichment analysis: a knowledge-based approach for**

- interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005, **102**:15545-15550.
25. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA: **Robust enumeration of cell subsets from tissue expression profiles.** *Nat Methods* 2015, **12**:453-457.
26. Long J, Chen P, Lin J, Bai Y, Yang X, Bian J, Lin Y, Wang D, Yang X, Zheng Y, et al: **DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma.** *Theranostics* 2019, **9**:7251-7267.
27. Yang Y, Lu Q, Shao X, Mo B, Nie X, Liu W, Chen X, Tang Y, Deng Y, Yan J: **Development Of A Three-Gene Prognostic Signature For Hepatitis B Virus Associated Hepatocellular Carcinoma Based On Integrated Transcriptomic Analysis.** *J Cancer* 2018, **9**:1989-2002.
28. Long J, Zhang L, Wan X, Lin J, Bai Y, Xu W, Xiong J, Zhao H: **A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma.** *J Cell Mol Med* 2018, **22**:5928-5938.
29. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: **The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.** *Cancer Discov* 2012, **2**:401-404.
30. Hou GX, Liu P, Yang J, Wen S: **Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using OncoPrint and Kaplan-Meier plotter.** *PLoS One* 2017, **12**:e0174515.
31. Galuppini F, Dal Pozzo CA, Deckert J, Loupakis F, Fassan M, Baffa R: **Tumor mutation burden: from comprehensive mutational screening to the clinic.** *Cancer Cell Int* 2019, **19**:209.
32. El-Serag HB, Rudolph KL: **Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.** *Gastroenterology* 2007, **132**:2557-2576.
33. Marquardt JU, Galle PR, Teufel A: **Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies.** *Journal of hepatology* 2012, **56**:267-275.
34. Wang Z, Gerstein M, Snyder M: **RNA-Seq: a revolutionary tool for transcriptomics.** *Nature reviews Genetics* 2009, **10**:57-63.
35. Xiao M, Liu L, Zhang S, Yang X, Wang Ya: **Cancer stem cell biomarkers for head and neck squamous cell carcinoma: A bioinformatic analysis.** *Oncology reports* 2018, **40**:3843-3851.
36. Wilson WR, Hay MP: **Targeting hypoxia in cancer therapy.** *Nat Rev Cancer* 2011, **11**:393-410.
37. Xiong XX, Qiu XY, Hu DX, Chen XQ: **Advances in Hypoxia-Mediated Mechanisms in Hepatocellular Carcinoma.** *Mol Pharmacol* 2017, **92**:246-255.
38. Yan H, Li Z, Shen Q, Wang Q, Tian J, Jiang Q, Gao L: **Aberrant expression of cell cycle and material metabolism related genes contributes to hepatocellular carcinoma occurrence.** *Pathol Res Pract* 2017, **213**:316-321.
39. Koppula P, Zhang Y, Zhuang L, Gan B: **Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer.** *Cancer Commun (Lond)* 2018, **38**:12.

40. Mollet J, Giurgea I, Schlemmer D, Dallner G, Chretien D, Delahodde A, Bacq D, de Lonlay P, Munnich A, Rotig A: **Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders.** *J Clin Invest* 2007, **117**:765-772.
41. Steuer CE, Ramalingam SS: **Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?** *J Clin Oncol* 2018, **36**:631-632.
42. Mamlouk S, Wielockx B: **Hypoxia-inducible factors as key regulators of tumor inflammation.** *Int J Cancer* 2013, **132**:2721-2729.
43. Nishida N, Kudo M: **Oncogenic Signal and Tumor Microenvironment in Hepatocellular Carcinoma.** *Oncology* 2017, **93 Suppl 1**:160-164.
44. Pardoll DM: **The blockade of immune checkpoints in cancer immunotherapy.** *Nat Rev Cancer* 2012, **12**:252-264.

Tables

Due to technical limitations, Tables 1-6 are only available as a download in the supplemental files section

Figures




Figure 1

Volcano plot showing the differentially expressed hypoxia-related genes of HCC in different databases. A Common differentially expressed genes between the TCGA and GEO databases. B Gene Ontology (GO) analysis of 397 hypoxia-related DEGs in HCC.




Figure 2

Consensus clustering of HCC molecular subgroups based on hypoxia-related DEGs. A Cumulative distribution function (CDF) curve. B CDF Delta area curve, which indicates the relative change in the area under the CDF curve for each category number k compared with $k-1$. The horizontal axis represents the number k and the vertical axis represents the relative change in the area under the CDF curve. C The Item-Consensus Plot for $k=4$. The vertical axis represents item-consensus values and each bar represents each sample. D The heatmap corresponding to the consensus matrix for $k=4$ obtained by applying consensus clustering. The rows and columns of the matrix represent samples. The values of the consistency matrix are shown in white to dark blue from 0 to 1, which represent the degree of consensus. E The heatmap of 397 hypoxia-related genes in 4 clusters.




Figure 3

Characterization of different features of hypoxia-related DEGs clustering. A-B K-M survival curves showed the differences of overall survival and recurrence rate among the 4 clusters. C Proportion of other clinical characteristics in 4 clusters. D-E The differences of TMB among 4 clusters.




Figure 4

Kaplan–Meier analysis, risk score analysis, time-dependent ROC analysis for a prognosis model based the three-gene signature in HCC. A-B K-M survival curve of high- and low-risk in TCGA cohort and ICGC cohort. C-D Time-dependent ROC analysis for OS prediction in TCGA and ICGC cohort.




Figure 5

Construction of the nomogram predicting overall survival for HCC patients in the TCGA cohort. A Forrest plot of the univariate and multivariate association of the prognostic model and clinicopathological characteristics with overall survival. B The nomogram was built based on two independent prognostic factors for predicting OS in HCC patients at 1-, 3-, and 5-year. C-E The calibration plot for internal validation of the nomogram. F-H Time-dependent ROC curves of the nomogram for 1-3- and 5-year overall survival in HCC to evaluate the predictive performance of the nomogram. I-K DCA curves of the

nomogram for 1-,3- and 5-year overall survival in HCC to evaluate the clinical decision-making benefits of the nomogram.




Figure 6

Kaplan–Meier analysis, risk score analysis, time-dependent ROC analysis for the recurrence model based on three-gene signature in HCC. A Distribution of risk scores of HCC patients with different gene expression levels in TCGA cohort. B The recurrence rate of high- and low-risk group in TCGA. C Time-dependent ROC analysis for recurrence prediction in TCGA cohort. D The ROC comparison between hypoxia-related recurrence signature and other recurrence models.




Figure 7

Construction of a recurrence nomogram for HCC patients in the TCGA cohort. A Forrest plot of the univariate and multivariate association of the risk-score model and clinicopathological characteristics with overall survival. B The nomogram was built based on three independent prognostic factors for predicting the recurrence in HCC patients at 1-, 3-, and 5-year. C-E The calibration plot for internal validation of the nomogram. F-H Time-dependent ROC AUCs of the nomogram for 1-,3- and 5-year recurrence prediction in HCC to evaluate the predictive performance of the nomogram. I-K DCA curves of

the nomogram for 1-,3- and 5-year recurrence prediction in HCC to evaluate the clinical decision-making benefits of the nomogram.




Figure 8

Building a diagnostic model for distinguishing HCC from normal samples. Sensitivity and specificity validation of the diagnostic model and ROC curves for evaluating the predictive performance. A-B in TCGA cohort. C-D in ICGC cohort. E-F in clinical specimens.




Figure 9

Building a diagnostic model for distinguishing HCC from dysplastic nodules. A and C sensitivity and specificity validation of the diagnostic model in the GSE6764 and GSE89377 cohort. B and D ROC curves for evaluating the predictive performance of the diagnostic model.




Figure 10

Validation of the expression characteristics of hypoxia-related genes. A Genetic alteration detection of the hypoxia-related genes from the cBioPortal database. B-D The expression level of each gene in TCGA cohort with 50 HCC samples paired 50 normal samples. E-G Real-time PCR analyses of the mRNA expressions of each gene in clinical specimens. H-J Real-time PCR analyses of the mRNA expressions of each gene in different cell lines. K-M The expression level of each gene in GSE6764 cohort with 35 HCC

samples paired 17 dysplastic nodules. O-Q The correlation analysis between expression levels of different genes in TCGA cohort with 370 HCC samples.




Figure 11

Prediction performance of hypoxia-related genes for OS and Gene Set Enrichment Analyses of the three-gene signature. A-C K-M survival curves for high and low expression levels of each gene. D-F progression-free survival analysis for high and low expression levels of each gene. G-I Three representative Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in high-risk group via GSEA.




Figure 12

The overview of immune infiltration and expression of immune checkpoints in HCC patients with different risk scores. A-C Violin plots showing infiltration fractions of different immune cells in the high- and low-risk groups. D-H Violin plots showing the expression level of immunocheckpoints in high- and low-risk groups.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigureS1.tif](#)
- [FigureS2revised.tif](#)
- [FigureS3revised.tif](#)
- [FigureS4revised.tif](#)
- [table1uniCox.xlsx](#)
- [table2GSE41666.xlsx](#)

- [table3GSE59729.xlsx](#)
- [table4TCGALHC.xlsx](#)
- [table5ICGCcohort.xlsx](#)
- [table6GSE14520cohort.xlsx](#)